VALENCIA, Calif., February 20, 2018 – Bioness Inc., the leading provider of cutting-edge, clinically supported rehabilitation therapies, today announced it will feature its full suite of innovative technologies at the American Physical Therapy Association’s (APTA) Combined Sections Meeting (CSM) from February 21-24 in New Orleans, LA. Attendees will have the chance to experience Bioness implantable and external neuromodulation systems, robotic systems, and software based therapy programs at booth #809.

“APTA-CSM represents an invaluable opportunity for the country’s leading rehabilitation healthcare professionals to gain practical knowledge and discover new technologies designed to help patients attain functional goals after life-changing events such as a stroke or other traumatic injury,” said Todd Cushman, President and CEO of Bioness. “This year, we’re excited to demonstrate several new innovations that give patients and therapists the highest level of control over the rehabilitation progress. These updates and technological developments reaffirm Bioness’ commitment to helping patients to thrive now and well into the future.”

Innovative clinical solutions to be featured by Bioness at APTA-CSM include:

L300 Go™ Functional Electrical Stimulation System
The recently FDA cleared L300 Go™ System is the first functional electrical stimulation (FES) device to provide 3D motion detection of gait events using a 3-axis gyroscope and accelerometer technology. Patients facing mobility challenges due to neurological injury or disease, such as stroke, multiple sclerosis, traumatic brain injury or spinal cord injury, have less control over their lower extremity muscles which increases fall risk and reduces social participation. By monitoring patient movement in all three planes of motion and deploying stimulation to provide ankle dorsiflexion and knee flexion or extension precisely when needed during the gait cycle, Bioness is further improving therapist efficiency in detecting a gait event. The L300 Go includes the myBioness™ mobile iOS application with activity tracking tools to keep home users engaged in the rehabilitation process and motivated to meet recovery goals. For the first time, CSM attendees will be able to experience a hands-on demonstration of the renovated myBioness™ app, currently pending FDA clearance, which provides users app based control over the L300 Go.

BITS® Bedside & Mobile Configurations
Most rehabilitation activities are designed to be performed from a standing position, however, many rehab patients are confined to their beds or restricted to seated activities for medical or safety reasons. To help tackle this challenge, Bioness has developed the BITS Bedside & Mobile configurations. The BITS Bedside configuration allows clinicians to engage rehab patients right at the bedside facilitating rehabilitative exercises for non-ambulatory patients. The BITS Mobile configuration is highly adaptable to challenging rehab environments where a full rehab gym is not available. With the BITS Bedside & Mobile configurations, clinicians can challenge and assess patients’ physical, visual, auditory, and cognitive abilities in virtually any treatment area. The BITS 2.0 software provides the ability to track and document progress with the goal of keeping patients engaged during this important phase of care.

Vector® Gait and Safety System with Intuitive Body Weight Support™
The Vector System with Intuitive Body Weight Support is Simply Smarter™. Intuitive Body Weight Support is a revolutionary innovation that allows patients to further the real-world experience in the clinic to properly prepare them for the community. Clinicians maintain unparalleled safety and control for their patients while permitting an unparalleled level of activity and interaction. The Vector Gait and Safety System is designed to improve patient mobility and functional independence while increasing patient and clinician safety. Parameters are based on a patient’s ability and/or activity which helps them gain confidence and allows clinicians to get more creative and aggressive during treatment. In addition, clinicians can run, record and document standardized tests to measure patient outcomes within the Vector software interface.

StimRouter® Neuromodulation System for Chronic Peripheral Pain
With an estimated 100 million people suffering from chronic pain, contributing more than $280 billion in annual costs to the U.S. healthcare system, there’s never been a greater need for innovative pain management options.¹ Specific to rehabilitation, shoulder pain is a common disability resulting from a central nervous system trauma (e.g. stroke). This pain traditionally originates at the axillary nerve, a peripheral nerve in the upper arm, and has been reported to occur in up to 85% of stroke survivors.² StimRouter is an implanted neuromodulation system designed to chronic pain of peripheral nerve origin (excluding the cranial facial region) by directly targeting pain at its point of origin, minimizing long-term healthcare costs and may providing pain relief compared to other treatments such as medications and injections which often have limited effect.³

H200® Wireless Hand Rehabilitation System
With more than 20 peer-reviewed and published clinical studies, the H200 System has been clinically shown to improve hand and upper extremity function during all stages of stroke rehabilitation. The System delivers non-invasive, functional electrical stimulation (FES) to improve hand function, reduce muscle spasms and prevent disuse atrophy. H200 Wireless is widely used in the Veterans Administration to promote functional hand use in spinal cord injury patients that lack the ability to perform daily activities including grasping and releasing hand movements.

Experience Bioness First Hand
Visit Bioness at APTA-CSM at booth #809. Be among the first to experience Bioness solutions in gait training, pain management and software therapy programs.

About StimRouter® Neuromodulation System

StimRouter is approved by the FDA to treat chronic pain of peripheral nerve origin, excluding pain in the craniofacial region. StimRouter is a minimally invasive neuromodulation medical device consisting of a thin, implanted lead with conductive electrode, external pulse transmitter (EPT), and hand-held wireless patient programmer. Electrical signals are transmitted transdermally from the EPT through the electrode, down the lead to the target nerve.

StimRouter is programmed at the direction of the physician to meet patient requirements but is controlled by the patient to address the patients’ specific, changing pain management needs

About Bioness Inc.

Bioness is the leading provider of innovative technologies helping people regain mobility and independence. Bioness solutions include implantable and external neuromodulation systems, robotic systems, and software based therapy programs providing functional and therapeutic benefits for individuals affected by pain, central nervous system disorders, and orthopedic injuries. Currently, Bioness offers six medical devices within its commercial portfolio which are distributed and sold on five continents and in over 25 countries worldwide. Our technologies have been implemented in the most prestigious and well-respected institutions around the globe with approximately 90% of the top rehabilitation hospitals in the United States currently using one or more Bioness solutions. Bioness has a singular focus on aiding large, underserved customer groups with innovative, evidence-based solutions and we will continue to develop and make commercially available new products that address the growing and changing needs of our customers. Individual results vary. Consult with a qualified physician to determine if this product is right for you. Contraindications, adverse reactions and precautions are available online at www.bioness.com.

Media Relations Contact Information
Next Step Communications
[email protected]
781.326.1741

¹ Institute of Medicine (US). Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education and Research. 2011. The National Academies.
² Van Ouwenaller, C. et al. 1986. Archives of Physical Medicine and Rehabilitation. 67, 23–26.
³ Deer T, et al. 2016. Neuromodulation. 19:91-100.